Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 4-6 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA Capture: The purified JK1RA-1 antibody is useful as the capture antibody in a sandwich ELISA assay, when used in conjunction with the biotinylated Poly5095 (Cat. No. 509501) antibody as the detecting antibody.
Description:
Interleukin-1 receptor antagonist (IL-1RA) is composed of three isoforms, one secreted (sIL-1Rα/IL-1Rα1), two intracellular (IL-1Rα2/IL-1Rα3) and produced by monocytes, tissue macrophages, Langerhans cells, dendritic cells, T and B cells, natural killer (NK) cells, large granular lymphocytes (LGL), vascular endothelium, smooth muscle, fibroblasts, thymic epithelia, astrocytes, microglia, glioma cells, keratinocytes, and chondrocytes. It is upregulated by IL-1β, IL-4, IL-6 and downregulated by glucocorticoids. The JK1RA-1 antibody reacts with human interleukin-1 receptor antagonist (IL-1RA).
Cytokine; three isoforms, one secreted (sIL-1Rα/IL-1Rα1), two intracellular (IL-1Rα2/IL-1Rα3); 17 kD (Mammalian)
Regulation:
Upregulated by IL-1β, IL-4, IL-6; downregulated by glucocorticoids
Cellular Sources:
Monocytes, tissue macrophages, Langerhans cells, dendritic cells, T and B cells, natural killer (NK) cells, large granular lymphocytes (LGL), vascular endothelium, smooth muscle, fibroblasts, thymic epithelia, astrocytes, microglia, glioma cells, keratino
Cellular Targets:
B cells, T cells, monocytes
Receptors:
Type I IL-1R (CDw121a), Type II IL-1R (CDw121b)
Bioactivity/Activities:
Storage forms that are released upon cell death to limit inflammation caused by cell debris; competitive inhibitor of IL-1 receptor binding; antagonizes IL-1 activities without having agonist effects; does not initiate intracellular signal transduction pr
Antigen References:
1. Carter, D., et al., 1990. Nature 344:633. 2. Chirivi, R., et al., 1993. Cancer Res. 53:5051. 3. Holtkamp, G., et al., 1999. Eur. J. Immunol. 29:215. 4. Kim, J., et al., 2003. Gene Ther. 10:1543.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
